menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Synthgene Biotechnology","sponsor":"Jiangsu Synthgene Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Synthgene Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Synthgene Biotechnology \/ Jiangsu Synthgene Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Synthgene Biotechnology \/ Jiangsu Synthgene Biotechnology"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Synthgene Biotechnology

    Menu

    Jiangsu Synthgene Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Synthgene Biotechnology

                            China arrow
                            VMX
                            Not Confirmed

                            Jiangsu Synthgene Biotechnology

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camrelizumab,SJ-Neo006,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Jinling Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

                            Details : Camrelizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 22, 2024

                            Lead Product(s) : Camrelizumab,SJ-Neo006,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Jinling Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.